Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma

Chun Yu Lo, Charalambos Michaeloudes, Pankaj K. Bhavsar, Chien Da Huang, Po Jui Chang, Chun Hua Wang, Han Pin Kuo, Kian Fan Chung

Research output: Contribution to journalArticle

Abstract

Background: Patients with severe asthma have increased airway remodelling and elevated numbers of circulating fibrocytes with enhanced myofibroblastic differentiation capacity, despite being treated with high doses of corticosteroids, and long acting β2-adrenergic receptor (AR) agonists (LABAs). We determined the effect of β2-AR agonists, alone or in combination with corticosteroids, on fibrocyte function. Methods: Non-adherent non-T cells from peripheral blood mononuclear cells isolated from healthy subjects and patients with non-severe or severe asthma were treated with the β2-AR agonist, salmeterol, in the presence or absence of the corticosteroid dexamethasone. The number of fibrocytes (collagen I+/CD45+ cells) and differentiating fibrocytes (α-smooth muscle actin+ cells), and the expression of CC chemokine receptor 7 and of β2-AR were determined using flow cytometry. The role of cyclic adenosine monophosphate (cAMP) was elucidated using the cAMP analogue 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) and the phosphodiesterase type IV (PDE4) inhibitor, rolipram. Results: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes from healthy subjects and non-severe asthma patients. Fibrocytes from severe asthma patients had a lower baseline surface β2-AR expression and were relatively insensitive to salmeterol but not to 8-Br-cAMP or rolipram. Dexamethasone increased β2-AR expression and enhanced the inhibitory effect of salmeterol on severe asthma fibrocyte differentiation. Conclusions: Fibrocytes from patients with severe asthma are relatively insensitive to the inhibitory effects of salmeterol, an effect which is reversed by combination with corticosteroids.

Original languageEnglish
Article number194
JournalRespiratory Research
Volume18
Issue number1
DOIs
Publication statusPublished - Nov 21 2017
Externally publishedYes

Fingerprint

Adrenergic Receptors
Asthma
Cyclic AMP
Adrenergic Agonists
Adrenal Cortex Hormones
Rolipram
Dexamethasone
CCR7 Receptors
Healthy Volunteers
CCR2 Receptors
Type 4 Cyclic Nucleotide Phosphodiesterase
Phosphodiesterase 4 Inhibitors
Airway Remodeling
8-Bromo Cyclic Adenosine Monophosphate
Smooth Muscle Myocytes
Actins
Blood Cells
Flow Cytometry
Collagen
Salmeterol Xinafoate

Keywords

  • CAMP
  • Corticosteroids
  • Fibrocytes
  • Severe asthma
  • β-adrenergic receptor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Lo, C. Y., Michaeloudes, C., Bhavsar, P. K., Huang, C. D., Chang, P. J., Wang, C. H., ... Chung, K. F. (2017). Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma. Respiratory Research, 18(1), [194]. https://doi.org/10.1186/s12931-017-0678-7

Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma. / Lo, Chun Yu; Michaeloudes, Charalambos; Bhavsar, Pankaj K.; Huang, Chien Da; Chang, Po Jui; Wang, Chun Hua; Kuo, Han Pin; Chung, Kian Fan.

In: Respiratory Research, Vol. 18, No. 1, 194, 21.11.2017.

Research output: Contribution to journalArticle

Lo, CY, Michaeloudes, C, Bhavsar, PK, Huang, CD, Chang, PJ, Wang, CH, Kuo, HP & Chung, KF 2017, 'Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma', Respiratory Research, vol. 18, no. 1, 194. https://doi.org/10.1186/s12931-017-0678-7
Lo, Chun Yu ; Michaeloudes, Charalambos ; Bhavsar, Pankaj K. ; Huang, Chien Da ; Chang, Po Jui ; Wang, Chun Hua ; Kuo, Han Pin ; Chung, Kian Fan. / Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma. In: Respiratory Research. 2017 ; Vol. 18, No. 1.
@article{0d1ce5fa25b549c7b0c02704bd3e917c,
title = "Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma",
abstract = "Background: Patients with severe asthma have increased airway remodelling and elevated numbers of circulating fibrocytes with enhanced myofibroblastic differentiation capacity, despite being treated with high doses of corticosteroids, and long acting β2-adrenergic receptor (AR) agonists (LABAs). We determined the effect of β2-AR agonists, alone or in combination with corticosteroids, on fibrocyte function. Methods: Non-adherent non-T cells from peripheral blood mononuclear cells isolated from healthy subjects and patients with non-severe or severe asthma were treated with the β2-AR agonist, salmeterol, in the presence or absence of the corticosteroid dexamethasone. The number of fibrocytes (collagen I+/CD45+ cells) and differentiating fibrocytes (α-smooth muscle actin+ cells), and the expression of CC chemokine receptor 7 and of β2-AR were determined using flow cytometry. The role of cyclic adenosine monophosphate (cAMP) was elucidated using the cAMP analogue 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) and the phosphodiesterase type IV (PDE4) inhibitor, rolipram. Results: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes from healthy subjects and non-severe asthma patients. Fibrocytes from severe asthma patients had a lower baseline surface β2-AR expression and were relatively insensitive to salmeterol but not to 8-Br-cAMP or rolipram. Dexamethasone increased β2-AR expression and enhanced the inhibitory effect of salmeterol on severe asthma fibrocyte differentiation. Conclusions: Fibrocytes from patients with severe asthma are relatively insensitive to the inhibitory effects of salmeterol, an effect which is reversed by combination with corticosteroids.",
keywords = "CAMP, Corticosteroids, Fibrocytes, Severe asthma, β-adrenergic receptor",
author = "Lo, {Chun Yu} and Charalambos Michaeloudes and Bhavsar, {Pankaj K.} and Huang, {Chien Da} and Chang, {Po Jui} and Wang, {Chun Hua} and Kuo, {Han Pin} and Chung, {Kian Fan}",
year = "2017",
month = "11",
day = "21",
doi = "10.1186/s12931-017-0678-7",
language = "English",
volume = "18",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Reduced suppressive effect of β2-adrenoceptor agonist on fibrocyte function in severe asthma

AU - Lo, Chun Yu

AU - Michaeloudes, Charalambos

AU - Bhavsar, Pankaj K.

AU - Huang, Chien Da

AU - Chang, Po Jui

AU - Wang, Chun Hua

AU - Kuo, Han Pin

AU - Chung, Kian Fan

PY - 2017/11/21

Y1 - 2017/11/21

N2 - Background: Patients with severe asthma have increased airway remodelling and elevated numbers of circulating fibrocytes with enhanced myofibroblastic differentiation capacity, despite being treated with high doses of corticosteroids, and long acting β2-adrenergic receptor (AR) agonists (LABAs). We determined the effect of β2-AR agonists, alone or in combination with corticosteroids, on fibrocyte function. Methods: Non-adherent non-T cells from peripheral blood mononuclear cells isolated from healthy subjects and patients with non-severe or severe asthma were treated with the β2-AR agonist, salmeterol, in the presence or absence of the corticosteroid dexamethasone. The number of fibrocytes (collagen I+/CD45+ cells) and differentiating fibrocytes (α-smooth muscle actin+ cells), and the expression of CC chemokine receptor 7 and of β2-AR were determined using flow cytometry. The role of cyclic adenosine monophosphate (cAMP) was elucidated using the cAMP analogue 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) and the phosphodiesterase type IV (PDE4) inhibitor, rolipram. Results: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes from healthy subjects and non-severe asthma patients. Fibrocytes from severe asthma patients had a lower baseline surface β2-AR expression and were relatively insensitive to salmeterol but not to 8-Br-cAMP or rolipram. Dexamethasone increased β2-AR expression and enhanced the inhibitory effect of salmeterol on severe asthma fibrocyte differentiation. Conclusions: Fibrocytes from patients with severe asthma are relatively insensitive to the inhibitory effects of salmeterol, an effect which is reversed by combination with corticosteroids.

AB - Background: Patients with severe asthma have increased airway remodelling and elevated numbers of circulating fibrocytes with enhanced myofibroblastic differentiation capacity, despite being treated with high doses of corticosteroids, and long acting β2-adrenergic receptor (AR) agonists (LABAs). We determined the effect of β2-AR agonists, alone or in combination with corticosteroids, on fibrocyte function. Methods: Non-adherent non-T cells from peripheral blood mononuclear cells isolated from healthy subjects and patients with non-severe or severe asthma were treated with the β2-AR agonist, salmeterol, in the presence or absence of the corticosteroid dexamethasone. The number of fibrocytes (collagen I+/CD45+ cells) and differentiating fibrocytes (α-smooth muscle actin+ cells), and the expression of CC chemokine receptor 7 and of β2-AR were determined using flow cytometry. The role of cyclic adenosine monophosphate (cAMP) was elucidated using the cAMP analogue 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) and the phosphodiesterase type IV (PDE4) inhibitor, rolipram. Results: Salmeterol reduced the proliferation, myofibroblastic differentiation and CCR7 expression of fibrocytes from healthy subjects and non-severe asthma patients. Fibrocytes from severe asthma patients had a lower baseline surface β2-AR expression and were relatively insensitive to salmeterol but not to 8-Br-cAMP or rolipram. Dexamethasone increased β2-AR expression and enhanced the inhibitory effect of salmeterol on severe asthma fibrocyte differentiation. Conclusions: Fibrocytes from patients with severe asthma are relatively insensitive to the inhibitory effects of salmeterol, an effect which is reversed by combination with corticosteroids.

KW - CAMP

KW - Corticosteroids

KW - Fibrocytes

KW - Severe asthma

KW - β-adrenergic receptor

UR - http://www.scopus.com/inward/record.url?scp=85034635784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034635784&partnerID=8YFLogxK

U2 - 10.1186/s12931-017-0678-7

DO - 10.1186/s12931-017-0678-7

M3 - Article

VL - 18

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 194

ER -